- Home
- UWMC vs PCRX Comparison
UWMC vs PCRX Comparison
Compare UWMC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- PCRX
- Stock Information
- Founded
- UWMC 1986
- PCRX 2006
- Country
- UWMC United States
- PCRX United States
- Employees
- UWMC N/A
- PCRX N/A
- Industry
- UWMC Finance: Consumer Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- PCRX Health Care
- Exchange
- UWMC Nasdaq
- PCRX Nasdaq
- Market Cap
- UWMC 940.0M
- PCRX 1.1B
- IPO Year
- UWMC N/A
- PCRX 2011
- Fundamental
- Price
- UWMC $5.49
- PCRX $24.85
- Analyst Decision
- UWMC Hold
- PCRX Buy
- Analyst Count
- UWMC 9
- PCRX 9
- Target Price
- UWMC $7.22
- PCRX $30.67
- AVG Volume (30 Days)
- UWMC 3.9M
- PCRX 866.2K
- Earning Date
- UWMC 05-08-2025
- PCRX 05-06-2025
- Dividend Yield
- UWMC 7.32%
- PCRX N/A
- EPS Growth
- UWMC N/A
- PCRX N/A
- EPS
- UWMC 0.13
- PCRX N/A
- Revenue
- UWMC $2,458,690,000.00
- PCRX $700,966,000.00
- Revenue This Year
- UWMC $10.38
- PCRX $9.37
- Revenue Next Year
- UWMC $23.99
- PCRX $11.30
- P/E Ratio
- UWMC $42.26
- PCRX N/A
- Revenue Growth
- UWMC 13.54
- PCRX 3.85
- 52 Week Low
- UWMC $5.31
- PCRX $11.16
- 52 Week High
- UWMC $9.74
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- UWMC 34.67
- PCRX 55.32
- Support Level
- UWMC $5.78
- PCRX $23.93
- Resistance Level
- UWMC $5.73
- PCRX $25.88
- Average True Range (ATR)
- UWMC 0.20
- PCRX 0.98
- MACD
- UWMC -0.05
- PCRX 0.19
- Stochastic Oscillator
- UWMC 12.79
- PCRX 74.57
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.